Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease

August 10, 2021 7:00 AM EDT

Achieved dose proportional pharmacodynamic changes in HBG mRNA and F-reticulocytes in whole blood Mean 4.5-fold induction in HBG mRNA at 10mg after 14 days of once-daily dosingMean 4.2-fold increase in F-reticulocytes at 10mg after 14 days of once-daily dosing Achieved maximal target engagement by day seven in 6mg and 10mg cohorts... More